Cargando…

Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study

BACKGROUND AND PURPOSE: Wearing-off is one of the most frequent problems encountered by levodopa-treated patients. Entacapone, a peripheral inhibitor of catechol-O-methyltransferase (COMT), reduces this motor complication by prolonging the effect of levodopa. We sought to understand the impact of CO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tambasco, Nicola, Muti, Marco, Chiarini, Pietro, Tarducci, Roberto, Caproni, Stefano, Castrioto, Anna, Nigro, Pasquale, Parnetti, Lucilla, Floridi, Pietro, Rossi, Aroldo, Calabresi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022515/ https://www.ncbi.nlm.nih.gov/pubmed/24830331 http://dx.doi.org/10.1371/journal.pone.0096806

Ejemplares similares

Complexity of Motor Sequences and Cortical Reorganization in Parkinson's Disease: A Functional MRI Study
por: Caproni, Stefano, et al.
Publicado: (2013)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
por: Tambasco, Nicola, et al.
Publicado: (2022)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Subclinical Visuospatial Impairment in Parkinson’s Disease: The Role of Basal Ganglia and Limbic System
por: Caproni, Stefano, et al.
Publicado: (2014)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
por: Tambasco, Nicola, et al.
Publicado: (2021)

Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
por: Kocer, Bilge, et al.
Publicado: (2016)

PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
por: Simoni, Simone, et al.
Publicado: (2022)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Lymphocytic colitis associated with entacapone
por: Rodrigues, David M., et al.
Publicado: (2022)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
por: Trenkwalder, Claudia, et al.
Publicado: (2019)

One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease
por: Ahn, Tae-Beom, et al.
Publicado: (2007)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Entacapone promotes hippocampal neurogenesis in mice
por: Yoo, Dae Young, et al.
Publicado: (2020)

Correction to “Lymphocytic colitis associated with entacapone”
Publicado: (2022)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Pumpentherapie bei fortgeschrittenem Parkinson-Syndrom: Charakterisierung des Intestinalgels Levodopa-Entacapon-Carbidopa
por: H. Jost, Wolfgang, et al.
Publicado: (2022)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Colite lymphocytaire associée à l’entacapone
por: Rodrigues, David M., et al.
Publicado: (2023)

Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks
por: Coppola, Gianluca, et al.
Publicado: (2022)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo(®))
por: Solla, Paolo, et al.
Publicado: (2010)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
por: Senek, M., et al.
Publicado: (2020)

Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of (123)I-FP-CIT Brain SPECT Data: Implications of Putaminal Findings and Age
por: Palumbo, Barbara, et al.
Publicado: (2014)

Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods
por: Caillava-Santos, Fabiane, et al.
Publicado: (2015)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

The Risk Factors for the Wearing-Off Phenomenon in Parkinson's Disease
por: Raja, Kunal, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
por: Fu, Shih-Chen, et al.
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ku32402nrkk81rau7bhl2tn62u